Loading...
Publication
Equidade no acesso a medicamentos oncológicos
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| PPG_25508 | 1.41 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Portugal possui uma política de saúde e medicamento cujo, principal, objetivo é promover a equidade no acesso aos cuidados de saúde e medicamentos, independentemente, das condições socioeconómicas ou culturais dos cidadãos. Contudo, face à crise mundial, devido ao coronavírus, o aumento da despesa em medicamentos e à criação de medicamentos inovadores muito caros, faz com que os orçamentos de saúde não consigam suportar de forma sustentável os custos resultantes da introdução de novas terapias no Sistema Nacional de Saúde (SNS).
Num cenário perfeito os custos em saúde deveriam ser vistos como um investimento, e não como uma despesa, cujo retorno é o aumento não só da esperança como, também, da qualidade de vida.
Portugal has a health and medicine policy whose main objective is to promote equity in access to health care and medicines, regardless of the socioeconomic or cultural conditions of the citizens. However, in the face of the global crisis, due to the coronavirus, the increase in spending on medicines and the creation of very expensive innovative medicines, means that health budgets cannot sustainably support the costs resulting from the introduction of new therapies in the national system of health. In an perfect scenario, health costs should be seen as an investment, and not as an expense, whose return is the increase not only in hope, but also, in the quality of life.
Portugal has a health and medicine policy whose main objective is to promote equity in access to health care and medicines, regardless of the socioeconomic or cultural conditions of the citizens. However, in the face of the global crisis, due to the coronavirus, the increase in spending on medicines and the creation of very expensive innovative medicines, means that health budgets cannot sustainably support the costs resulting from the introduction of new therapies in the national system of health. In an perfect scenario, health costs should be seen as an investment, and not as an expense, whose return is the increase not only in hope, but also, in the quality of life.
Description
Keywords
Políticas da saúde e medicamento Oncologia Farmacêutico clínico Health and medicine policies Oncology Clinical pharmacist